➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Merck
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Litigation Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Docket   Start Trial Date Filed 2014-07-03
Court District Court, D. Delaware Date Terminated 2016-11-16
Cause 35:271 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To Judge Sherry R. Fallon
Parties APOTEX INC.; MERCK SHARP & DOHME CORP.; TEVA PHARMACEUTICALS USA INC.
Patents 6,127,353
Attorneys Andrew E. Riley; Aviv Zalcenstein; Bindu Ann George Palapura; David Ellis Moore; David M. Hashmall; Frederick H. Rein; Ira J. Levy; Joseph B. Crystal; Joshua A. Whitehill; Joshua P. Davis; Lindsay M. Volpenhein; Lisa M. Thomas; Michael B. Cottler; Michelle J. Eber; Nicolas G. Barzoukas; Richard L. Horwitz
Link to Docket External link to docket
Small Molecule Drugs cited in Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Merck Sharp & Dohme Corp. v. Teva Pharmaceuticals USA Inc. (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-07-03 1 product, prior to expiration of U.S. Patent No. 6,127,353 (“the ’353 patent”). PARTIES 2. Merck is a New Jersey…ACTION l. This is an action for patent infringement arising under the patent laws of the United States of…which is claimed in the ’353 patent, before the expiration of the ’353 patent, On information and belief…expiration of the ’353 patent, Teva was aware of the existence of the ’353 patent and that the filing of…which is claimed in the ’353 patent, before the expiration of the ’353 patent. On information and belief External link to document
2014-07-31 13 previously held, after trial, that U.S. Patent No. 6,127,353 (“the ‘353 patent”; D.I. 1-1) was not infringed …mometasone furoate infringes the ‘353 patent, even though that patent is directed to mometasone furoate…for Infringement of the ‘353 Patent Based on its Anhydrous Mometasone…for Infringement of the ‘353 Patent Based on its Anhydrous Mometasone… Sheridan Has Already Considered the ‘353 Patent and the Issue of Infringement External link to document
2015-09-03 132 alleging infringement of U.S. Patent No. 6, 127,353 ("the '353 patent") ("New Jersey/…henceforth will be to Civ. No. 14-874. to work on patent infringement litigation "relating to the drug…Merck failed to prove infringement of the '353 patent and dismissed Merck's claims. (Id., ex. 7A)…July 2014, asserting infringement of the '353 patent. Merck instituted Civ. No. 15-250 against defendant…March 2015, asserting infringement of the '353 patent. Also in March 2015, Merck instituted a second External link to document
2015-09-03 133 disputed claim language of U.S. Patent No. 6,127,353 ("the '353 patent") shall be construed…quot;Mometasone furoate monohydrate." The patented invention "relates to the novel compound… 16 November 2016 1:14-cv-00874-SLR-SRF Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Boehringer Ingelheim
McKinsey
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.